STAT+: Illumina chief commercial officer leaves to lead liquid biopsy startup Delfi
Delfi Diagnostics, a startup devising new ways to use routine blood draws to detect early…
Category: STAT+
STAT+: Allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer
Allogene Therapeutics is making unexpected changes to development plans for its off-the-shelf cell therapy for…
.jpg)
STAT+: Feng Zhang’s year-old CRISPR delivery startup Aera lays off quarter of staff
Aera Therapeutics, a startup launched by the CRISPR pioneer Feng Zhang last year to solve…
STAT+: Another major pharma company departs BIO
WASHINGTON — UCB left BIO at the end of 2023, the second major member company to…
STAT+: Pharmalittle: We’re reading about CVS dropping Humira coverage, pharma layoffs, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: An injectable gel enters the male birth control fray with early positive clinical data
Between condoms and vasectomies lies a vast, undeveloped chasm of male birth control. Contraline, a…
STAT+: Feng Zhang, Grail founder join forces on new gene editing startup, Moonwalk
A new startup co-founded by CRISPR innovator Feng Zhang, a former executive at Grail and…
STAT+: Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs
Novo Nordisk may already have one blockbuster obesity drug in its portfolio, but the Danish…
STAT+: Burning questions for the 2024 JPM Healthcare Conference
The J.P. Morgan Healthcare Conference is upon us, bringing its frenetic meetings, crowded hallways, and…
STAT+: Health tech’s 2024 hiring outlook: Balance tips toward employers
Health tech hopefuls might once have been used to a wealth of job options, especially…
STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news
Hello, everyone, and how are you today? We are doing fine, thank you, especially given…
STAT+: Goldman Sachs launches $650 million fund for life science investments
Investment bank Goldman Sachs is jumping into the biotech world after raising $650 million to…
STAT+: AI tools and a desire to do more with less is expected to drive health systems’ 2024 tech spend
Hospitals and clinics are expecting a slightly better 2024 compared to last year thanks to…
.jpg)
STAT+: Consumer health advocate Sid Wolfe was a thorn in the side. We’re all the better as a result
The first phone call came some time in late 1996. “Ed, I’d like to introduce…
STAT+: A single drug and multiple study failures leave Anavex with nothing but cash
It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage…
STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles
Good morning, everyone, and welcome to another working week, and a new year, as well….
STAT+: Here’s who’s profiting the most in health care
For all the flack they get, the country’s four biggest pharmacy benefit managers reported a…
STAT+: 3 health policies states are taking on in 2024
For most states, the new year means a new legislative session. STAT’s taking a look…
STAT+: UnitedHealth used secret rules to restrict rehab care for seriously ill Medicare Advantage patients
Health insurance giant UnitedHealth Group used secret rules to restrict access to rehabilitation care requested…
STAT+: Apple Watches are back on sale while federal court reviews patent suit
Apple Watches are back on the market. In a last minute win for the company,…
STAT+: Philips pays $2.4 million for allegedly giving kickbacks to sleep labs
Philips agreed to pay $2.4 million to settle allegations that the free masks it gave…
STAT+: Cytokinetics heart drug aficamten succeeds in pivotal study
An experimental medicine from Cytokinetics significantly improved exercise capacity for patients with a rare, progressive…
STAT+: What comes after Wegovy? The quest to eradicate obesity
About a decade ago, after becoming obese, Jacob Petersen lost weight so quickly that some…
STAT+: 3 FDA staffers to watch in 2024
WASHINGTON — The Food and Drug Administration has a lot on its plate in 2024…
STAT+: 3 issues to watch in pharma in 2024
As another year comes to an end and the world seems to hit the proverbial…
STAT+: Complications spiked 25% in hospitals bought by private equity
There’s ample evidence that private equity buyouts in health care drive up costs. A new…
STAT+: With Biden finalizing an Apple Watch ban, Apple needs to decide its future in health
An import ban of certain Apple Watches officially goes into effect on Tuesday, after the…
STAT+: Bristol Myers will pay $4.1 billion for cancer startup RayzeBio
Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into…
STAT+: New weight loss drugs have proven their effectiveness. Now researchers want to know how to best use them
LONDON — Starting in the new year, a team of researchers in the U.K. and…
STAT+: 3 CRISPR advances to watch in 2024
Life in the CRISPR lane tends to move at lightning speed. This year saw the…
STAT+: 3 medtech trends to watch in 2024
It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was…
STAT+: FDA alters warning label for Carvykti CAR-T, although link to secondary cancers is unclear
The Food and Drug Administration issued a change to the warning label for Legend Biotech…
STAT+: Venture capital is still pouring into drug research despite Medicare price negotiation
WASHINGTON — Venture capitalists are still pouring money into drug research in spite of Medicare’s…
STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud
And so, another working week will soon come to a close. Not a moment too…
STAT+: Bristol Myers to purchase Karuna, maker of schizophrenia drug, for $14 billion
Bristol Myers Squibb said Friday that it will acquire Karuna Therapeutics, a developer of medicines…
STAT+: AAFP’s CEO on how to keep primary care doctors in the field
In ten years, the United States could be short as many as 48,000 primary care…
STAT+: Pharmalittle: FDA rejects Merck cough medicine; Sanofi abandons an ADC for lung cancer
Good morning, everyone. Damian Garde here, filling in for Ed Silverman in a week customarily…
STAT+: Patent thickets and terminal disclaimers: How pharma blocks biosimilars from the marketplace
To ring the register, a pharmaceutical company may create a patent thicket, which involves filing…
STAT+: Medical marijuana companies are using pharma’s sales tactics with little of the same scrutiny
WASHINGTON — Medical marijuana companies sell medicine, just like pharmaceutical companies. But they’re not playing…
STAT+: Drugs are still mostly tested in white men. Will the FDA change that next year?
WASHINGTON — Sometime next year drug and medical device companies will have to tell the…
STAT+: SEC charges former CEO of pain relief device company with $41 million fraud
The Securities and Exchange Commission on Tuesday charged the former CEO of Stimwave, a company…
STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernathy to step down as Verily CMO
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: In another blow, Argenx antibody therapy fails in trial for skin blistering condition
LONDON — The Belgian company Argenx said Wednesday that its closely watched antibody therapy failed…
STAT+: 3 trends to watch in biotech in 2024
Every winter, like Punxsutawney nobles, biotech’s many thought leaders gather in San Francisco to pick…
STAT+: Amy Abernethy to step down as Verily’s chief medical officer in latest departure from company
Amy Abernethy, the president of product development and chief medical officer at Verily, a health…
STAT+: Pharmalittle: Weight loss drugs are being paired with bariatric surgery; Carl Icahn plans to oust Illumina directors
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: In the U.S., scientists see barriers to the development of CAR-T therapies. In Spain, a hospital brews its own
BARCELONA, Spain — Some of the patients waiting in the oncology ward of a hospital…
What the new health counsels at FTC, DOJ, and HHS might do
Three major government agencies are adding new officials to investigate price-gouging in health care —…
Here are the worst biopharma CEOs of 2023
Pfizer is this year’s anti-Eli Lilly. If David Ricks is the best biopharma CEO of…